BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pletikosic S, Plavsic I, Hauser G, Tkalcic M. Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity. Med Hypotheses. 2015;85:339-342. [PMID: 26112162 DOI: 10.1016/j.mehy.2015.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee SH, Kim CR, Kim KN. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome. Am J Med Sci 2019;357:23-8. [PMID: 30611316 DOI: 10.1016/j.amjms.2018.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jiang CZ, Yan XZ. Fecal calprotectin for diagnosis of digestive system diseases. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 4069-4074 [DOI: 10.11569/wcjd.v23.i25.4069] [Reference Citation Analysis]
3 Tsigaridas A, Anagnostopoulos AK, Papadopoulou A, Ioakeim S, Vaiopoulou A, Papanikolaou IS, Viazis N, Karamanolis G, Mantzaris GJ, Tsangaris GT, Gazouli M. Identification of serum proteome signature of irritable bowel syndrome: Potential utility of the tool for early diagnosis and patient's stratification. Journal of Proteomics 2018;188:167-72. [DOI: 10.1016/j.jprot.2017.07.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]